ASH 2018 | RUXOPEG: a promising novel combination for MPN-associated myelofibrosis

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the RUXOPEG trial (NCT02742324) of ruxolitinib and pegylated interferon alpha 2a for myeloproliferative neoplasm-associated myelofibrosis. Prof. Kiladjian covers the initial efficacy and safety results of this novel combination from the first study to formally assess this, before explaining further plans for this regimen. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video